Anuh Pharma Limited (BOM:506260)
India · Delayed Price · Currency is INR 82.74
-2.69 (-3.15%)
At close: May 6, 2026
Anuh Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 473.52 | 600.58 | 361.8 | 305.61 | 284.36 |
Depreciation & Amortization | 86.42 | 84.87 | 96.49 | 119.02 | 150.19 |
Other Amortization | 0.98 | 0.97 | 0.51 | 0.57 | 0.57 |
Loss (Gain) From Sale of Assets | -0.17 | - | -0.15 | -0.62 | 0.32 |
Asset Writedown & Restructuring Costs | 0.01 | 0.22 | - | - | - |
Loss (Gain) From Sale of Investments | -68.88 | -107.21 | -43.39 | -26.37 | -80.44 |
Provision & Write-off of Bad Debts | - | - | -2 | -0.51 | 3.84 |
Other Operating Activities | 10.01 | -14.35 | -37.92 | -16.19 | 3.64 |
Change in Accounts Receivable | -271.16 | -187.47 | -354.96 | -287.96 | -258.25 |
Change in Inventory | 9.19 | -27.64 | 72.87 | 15.03 | -199.38 |
Change in Accounts Payable | 177.27 | -125.87 | 322.22 | 15.58 | 153.77 |
Change in Other Net Operating Assets | -45.94 | -94.84 | 123.53 | 164.47 | -245.97 |
Operating Cash Flow | 371.25 | 129.25 | 539.02 | 288.64 | -187.35 |
Operating Cash Flow Growth | 187.23% | -76.02% | 86.75% | - | - |
Capital Expenditures | -201.46 | -50.17 | -15.5 | -16.15 | -61.54 |
Sale of Property, Plant & Equipment | - | - | 0.57 | 1.43 | 1.1 |
Investment in Securities | -12.14 | 47.87 | -438.14 | -86.59 | 562.16 |
Other Investing Activities | 14.51 | 11.48 | 18.24 | 23.14 | 20.32 |
Investing Cash Flow | -199.09 | 9.18 | -434.84 | -78.17 | 522.03 |
Short-Term Debt Issued | 84.85 | 20.13 | - | - | - |
Total Debt Issued | 84.85 | 20.13 | - | - | - |
Short-Term Debt Repaid | - | - | -31.11 | -104.87 | -309.62 |
Long-Term Debt Repaid | -3.46 | -3.08 | -3.08 | -3.35 | -5.5 |
Total Debt Repaid | -3.46 | -3.08 | -34.19 | -108.22 | -315.13 |
Net Debt Issued (Repaid) | 81.38 | 17.06 | -34.19 | -108.22 | -315.13 |
Common Dividends Paid | -125.22 | -100.25 | -87.48 | -75.58 | - |
Other Financing Activities | -4.76 | -2.49 | -1.2 | -10.7 | -16.03 |
Financing Cash Flow | -48.6 | -85.68 | -122.87 | -194.49 | -331.15 |
Net Cash Flow | 123.56 | 52.75 | -18.69 | 15.97 | 3.53 |
Free Cash Flow | 169.79 | 79.09 | 523.52 | 272.49 | -248.89 |
Free Cash Flow Growth | 114.69% | -84.89% | 92.12% | - | - |
Free Cash Flow Margin | 2.57% | 1.22% | 9.93% | 5.60% | -5.76% |
Free Cash Flow Per Share | 1.69 | 0.79 | 5.22 | 2.72 | -2.48 |
Cash Interest Paid | 4.76 | 2.49 | 1.2 | 10.69 | 16.24 |
Cash Income Tax Paid | 111.22 | 190.7 | 134.67 | 91.38 | 97.3 |
Levered Free Cash Flow | 133.71 | 125.18 | 479.05 | 254.68 | -346.58 |
Unlevered Free Cash Flow | 137.58 | 127.39 | 480.42 | 260.69 | -337.24 |
Change in Working Capital | -130.63 | -435.81 | 163.67 | -92.89 | -549.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.